Companies / Germany
German Drug Firms Slam Healthcare Reforms
August 2006 | Legal NewsGerman pharmaceutical companies have strongly criticised a Health Ministry working paper on the healthcare reform draft legislation which could lead to price caps for newly launched branded drugs. In what they see as a blow to innovation, domestic companies Schwarz Pharma and Schering AG said that the limitations of pricing will lead to less money to fund the research and development of new medicines.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
